JC polyomavirus DNA detection in clinical practice.

Current clinical guidelines lack clear guidance on when to test for JC polyomavirus DNA. While JCPyV is known to cause progressive multifocal leukoencephalopathy (PML), its diagnostic utility remains unclear in many settings. Prior research has established that JCPyV can persist in immunosuppressed individuals. However, no prior work had resolved how frequently JCPyV testing leads to actionable diagnoses. This gap motivated a retrospective analysis of clinical records to assess the real-world use of JCPyV DNA PCR. The study aimed to clarify in which patient groups JCPyV detection is most informative. No prior work had resolved whether plasma samples are reliable for JCPyV screening. The researchers focused on patients with neurological symptoms or organ transplants. This uncertainty drove the need to evaluate diagnostic outcomes across multiple sample types.

The study aimed to evaluate the clinical utility of JCPyV DNA detection in various patient populations. Researchers sought to identify in which clinical scenarios JCPyV testing is most useful. They reviewed records of 410 patients who had JCPyV DNA PCR performed on CSF, plasma, urine, or tissue samples. The goal was to determine how often JCPyV detection led to a diagnosis of PML. The researchers also wanted to assess whether plasma samples are reliable for JCPyV screening. They focused on patients with neurological symptoms or immunosuppressive conditions. The study aimed to clarify the role of JCPyV testing in transplant recipients. This analysis sought to guide future clinical decision-making regarding JCPyV diagnostics.

The researchers conducted a retrospective analysis of clinical records from 2012 to 2018. They included 410 patients who had JCPyV DNA PCR performed on CSF, plasma, urine, or tissue samples. Patient records were reviewed for underlying diseases and clinical indications for testing. The study categorized patients based on medical history such as transplantation, malignancies, or neurological symptoms. JCPyV DNA was analyzed in 224 plasma, 190 CSF, 32 urine, and 10 tissue samples. The researchers recorded the reasons for sample collection and whether JCPyV detection led to a diagnosis. They assessed the frequency of PML diagnosis in patients with JCPyV-positive results. The study compared the usefulness of different sample types in diagnosing PML.

JCPyV DNA detection led to a diagnosis of PML in 8 out of 410 patients (2.0%). Seven of these patients had hematologic malignancies as an underlying condition. CSF and brain biopsy samples were most useful in confirming PML. Plasma samples did not contribute to PML diagnosis in this cohort. Most urine samples were collected from kidney transplant patients for monitoring. JCPyV detection was most informative in immunosuppressed patients with neurological symptoms. The study found no role for plasma samples in diagnosing JCPyV-associated nephropathy. BK polyomavirus was identified as the primary cause of polyomavirus nephropathy in this population.

The study suggests that JCPyV DNA detection is most useful in immunosuppressed patients with neurological symptoms. CSF and brain biopsy samples are recommended when PML is suspected. Plasma samples are not reliable for diagnosing PML or JCPyV-associated nephropathy. JCPyV detection is valuable in patients with a history of immunosuppressive therapy. The findings support the use of JCPyV PCR in patients with hematologic malignancies or neurological symptoms. Urine samples are primarily used for monitoring kidney transplant patients. The study proposes that JCPyV testing should be reserved for cases with clinical suspicion of PML. These conclusions align with the observed low yield of JCPyV detection in plasma samples.